237 related articles for article (PubMed ID: 28781079)
1. Rapid Generation of Human Genetic Loss-of-Function iPSC Lines by Simultaneous Reprogramming and Gene Editing.
Tidball AM; Dang LT; Glenn TW; Kilbane EG; Klarr DJ; Margolis JL; Uhler MD; Parent JM
Stem Cell Reports; 2017 Sep; 9(3):725-731. PubMed ID: 28781079
[TBL] [Abstract][Full Text] [Related]
2. Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.
Thamodaran V; Rani S; Velayudhan SR
Methods Mol Biol; 2022; 2454():755-773. PubMed ID: 33830454
[TBL] [Abstract][Full Text] [Related]
3. Fast and Efficient Generation of Isogenic Induced Pluripotent Stem Cell Lines Using Adenine Base Editing.
Nami F; Ramezankhani R; Vandenabeele M; Vervliet T; Vogels K; Urano F; Verfaillie C
CRISPR J; 2021 Aug; 4(4):502-518. PubMed ID: 34406036
[TBL] [Abstract][Full Text] [Related]
4. Efficient Generation and Correction of Mutations in Human iPS Cells Utilizing mRNAs of CRISPR Base Editors and Prime Editors.
Sürün D; Schneider A; Mircetic J; Neumann K; Lansing F; Paszkowski-Rogacz M; Hänchen V; Lee-Kirsch MA; Buchholz F
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32384610
[TBL] [Abstract][Full Text] [Related]
5. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
6. Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9.
Ben Jehuda R; Shemer Y; Binah O
Stem Cell Rev Rep; 2018 Jun; 14(3):323-336. PubMed ID: 29623532
[TBL] [Abstract][Full Text] [Related]
7. Homozygous might be hemizygous: CRISPR/Cas9 editing in iPSCs results in detrimental on-target defects that escape standard quality controls.
Simkin D; Papakis V; Bustos BI; Ambrosi CM; Ryan SJ; Baru V; Williams LA; Dempsey GT; McManus OB; Landers JE; Lubbe SJ; George AL; Kiskinis E
Stem Cell Reports; 2022 Apr; 17(4):993-1008. PubMed ID: 35276091
[TBL] [Abstract][Full Text] [Related]
8. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.
Paquet D; Kwart D; Chen A; Sproul A; Jacob S; Teo S; Olsen KM; Gregg A; Noggle S; Tessier-Lavigne M
Nature; 2016 May; 533(7601):125-9. PubMed ID: 27120160
[TBL] [Abstract][Full Text] [Related]
9. Induced Pluripotent Stem Cells Meet Genome Editing.
Hockemeyer D; Jaenisch R
Cell Stem Cell; 2016 May; 18(5):573-86. PubMed ID: 27152442
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming of Fibroblasts to Human iPSCs by CRISPR Activators.
Weltner J; Trokovic R
Methods Mol Biol; 2021; 2239():175-198. PubMed ID: 33226620
[TBL] [Abstract][Full Text] [Related]
11. Editing the Genome of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9 Ribonucleoprotein Complexes.
Bruntraeger M; Byrne M; Long K; Bassett AR
Methods Mol Biol; 2019; 1961():153-183. PubMed ID: 30912046
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-Mediated Introduction of Specific Heterozygous Mutations in Human Induced Pluripotent Stem Cells.
Brandão KO; Grandela C; Yiangou L; Mummery CL; Davis RP
Methods Mol Biol; 2022; 2454():531-557. PubMed ID: 33755904
[TBL] [Abstract][Full Text] [Related]
13. Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9.
Yumlu S; Stumm J; Bashir S; Dreyer AK; Lisowski P; Danner E; Kühn R
Methods; 2017 May; 121-122():29-44. PubMed ID: 28522326
[TBL] [Abstract][Full Text] [Related]
14. High-Level Precise Knockin of iPSCs by Simultaneous Reprogramming and Genome Editing of Human Peripheral Blood Mononuclear Cells.
Wen W; Cheng X; Fu Y; Meng F; Zhang JP; Zhang L; Li XL; Yang Z; Xu J; Zhang F; Botimer GD; Yuan W; Sun C; Cheng T; Zhang XB
Stem Cell Reports; 2018 Jun; 10(6):1821-1834. PubMed ID: 29754960
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-mediated editing of ACTB in induced pluripotent stem cells: A model for investigating human ACTB loss-of-function and genetic adaptive responses.
Binder S; Ramachandran H; Haslinger D; Hildebrandt B; Dobner J; Haarmann-Stemmann T; Chiocchetti A; Rossi A
Stem Cell Res; 2024 Jun; 77():103395. PubMed ID: 38518401
[TBL] [Abstract][Full Text] [Related]
16. Use of CRISPR/Cas ribonucleoproteins for high throughput gene editing of induced pluripotent stem cells.
Wang Q; Chear S; Wing K; Stellon D; Nguyen Tran MT; Talbot J; Pébay A; Hewitt AW; Cook AL
Methods; 2021 Oct; 194():18-29. PubMed ID: 33607266
[TBL] [Abstract][Full Text] [Related]
17. Efficient Cas9-based Genome Editing Using CRISPR Analysis Webtools in Severe Early-onset-obesity Patient-derived iPSCs.
Patel A; Iannello G; Diaz AG; Sirabella D; Thaker V; Corneo B
Curr Protoc; 2022 Aug; 2(8):e519. PubMed ID: 35950852
[TBL] [Abstract][Full Text] [Related]
18. Generation of Human Isogenic Induced Pluripotent Stem Cell Lines with CRISPR Prime Editing.
Bonnycastle LL; Swift AJ; Mansell EC; Lee A; Winnicki E; Li ES; Robertson CC; Parsons VA; Huynh T; Krilow C; Mohlke KL; Erdos MR; Narisu N; Collins FS
CRISPR J; 2024 Feb; 7(1):53-67. PubMed ID: 38353623
[TBL] [Abstract][Full Text] [Related]
19. Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells.
Prat F; Toutain J; Boutin J; Amintas S; Cullot G; Lalanne M; Lamrissi-Garcia I; Moranvillier I; Richard E; Blouin JM; Dabernat S; Moreau-Gaudry F; Bedel A
Stem Cell Reports; 2020 Sep; 15(3):677-693. PubMed ID: 32795423
[TBL] [Abstract][Full Text] [Related]
20. Genome Editing Using Cas9-gRNA Ribonucleoprotein in Human Pluripotent Stem Cells for Disease Modeling.
Benetó N; Grinberg D; Vilageliu L; Canals I
Methods Mol Biol; 2022; 2549():409-425. PubMed ID: 33755903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
